Legend swung to operating income of $46.8 million from a $43.3 million loss a year ago, with CARVYKTI net trade sales up 36% globally. Revenue landed in line with estimates, so the upside came from cost discipline. Updated NCCN guidelines now prefer CAR-T at first relapse, opening second and third lines.
Latest Activity
LEGN Coverage
Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Marriott International, Merck, Novo Nordisk, Okta, and More
With all eyes locked on this morning's CPI release and the Strait of Hormuz nearly shut down, Wall Street analysts are already repositioning across hospitality, pharma, and tech before the market even…
Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus
Legend Biotech just posted a quarter that flipped a key narrative for LEGN shareholders, but with a CEO transition underway and the stock still down sharply over the past year, the real…
After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching
Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and three names keep surfacing in deal speculation. One already has a natural buyer…
Big Pharma’s 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth. Five therapeutic categories are absorbing most strategic capital: radiopharmaceuticals, next-gen GLP-1,…
Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Callaway Golf, Datadog, Hyatt Hotels, Palantir, Texas Instruments, Verizon, and More
Pre-Market Stock Futures: The futures are trading higher this morning, following a solid bounce-back rally across the major indices on Wednesday, after the worst day for stocks since October. Stocks were headed…